Surgery Partners, Inc. - Common Stock (SGRY)

Let’s dig into the relative performance of agilon health (NYSE:AGL) and its peers as we unravel the now-completed Q4 outpatient & specialty care earnings season.

Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 17.5% year on year to $864.4 million. The company expects the full year’s revenue to be around $3.38 billion, close to analysts’ estimates. Its non-GAAP profit of $0.44 per share was 16.7% above analysts’ consensus estimates.

Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results tomorrow before market open. Here’s what you need to know.

Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners experiencing significant growth due to strategic developments.

Promising Signs: SURGERY PARTNERS INC Setting the Stage for a Breakout.

Concentra, a subsidiary of select medical, recently priced its IPO at $23.50 per share. Concentra offers occupational health services with 547 centers in 41 states.

SGRY stock results show that Surgery Partners beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Top mid-cap stock performers: VIRT (+30%), VFC (+22%), NFE (+20%), RIOT (+16%), CLVT (+14%), AMN (+14%), BKU (+13%), MARA (+12%), EXPI (+12%), ZETA (+11%), NATL (+11%).

SGRY stock results show that Surgery Partners beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak quarterly sales.